MM

Cecilia BrownMyeloma | November 22, 2022
A triplet treatment plus autologous stem-cell transplantation was associated with longer progression...
Cecilia BrownMyeloma | November 22, 2022
Treatment with teclistamab, a T-cell–redirecting bispecific antibody, led to a “high rate of deep and durable...
Leah SherwoodMyeloma | November 22, 2022
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use issued...
Advertisement
Leah SherwoodMyeloma | November 16, 2022
Among 37 evaluable patients, the ORR was 78%, and 27 patients had a VGPR or better...
Leah LawrenceMyeloma | November 16, 2022
The study explored adding daratumumab to RVd and VTd regimens for patients with multiple myeloma...
Leah LawrenceMyeloma | February 3, 2023
The median PFS with the three-drug combination was higher compared with carfilzomib and dexamethasone alone.
Advertisement
Leah LawrenceMyeloma | February 3, 2023
Adding ixazomib to this treatment regimen did not improve survival outcomes, according to results of the MUKeight trial
Leah LawrenceMyeloma | November 14, 2022
A phase I study is underway to assess ALLO-605.
Sabrina AhleMyeloma | November 14, 2022
Cilta-cel has been approved by the FDA for the treatment of patients with relapsed or refractory multiple myeloma who have ...
Patrick DalyMyeloma | November 14, 2022
Teclistamab produced meaningful and durable responses in patients with heavily pretreated relapsed or refractory multiple ...
Brandon MayMyeloma | November 14, 2022
Researchers explored whether population-based screening for MGUS could increase the frequency of patients with multiple ...
Sabrina AhleMyeloma | November 14, 2022
Post-transplant response-adapted consolidation therapy with Dara-KRd using MRD led to high rates of MRD negativity in ...
Sabrina AhleMyeloma | November 14, 2022
Daratumumab and hyaluronidase-fihj, in combination with carfilzomib and dexamethasone (Kd), has received U.S. Food and Drug ...
Rebecca AraujoMyeloma | November 19, 2021
Researchers sought to calculate healthcare costs associated with triple class exposure to multiple myeloma.
Rebecca AraujoMantle Cell Lymphoma | February 1, 2023
Patients in the trial were treated for lymphoma, leukemia, or multiple myeloma.
Rebecca AraujoMyeloma | November 14, 2022
A study published in Internal Medicine evaluated the safety profile of ixazomib in a cohort of Japanese patients with ...
Rob DillardMyeloma | November 14, 2022
Researchers sought to discern the effect of COVID-19 countermeasures on treatment outcomes in a patient population receiving ...
Advertisement
Advertisement
Editorial Board